2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Hepatitis B Market?
The chronic hepatitis B virus market’s growth is likely to be fueled by the widespread incidence of chronic hepatitis B infection. Hepatitis B, a liver infection caused by the hepatitis B virus (HBV), can be averted via immunization. A surge in hepatitis B infection rates is frequently linked to a range of factors, particularly in low- and middle-income countries, where inadequate vaccination coverage results in higher transmission rates due to a significant proportion of the population remaining unvaccinated. An escalation in hepatitis B infection rates can boost the demand for diagnostic tests and treatment alternatives. For instance, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, released a report in June 2024 indicating that increasing global hepatitis B vaccination coverage to 90% and enhancing access to treatment to 80% could help avert 26 million new infections and 9 million deaths due to hepatitis B between 2022 and 2050. As of 2022, there have been 1.2 million new cases of hepatitis B virus (HBV) infection. Consequently, the chronic hepatitis B virus market is likely to be spurred by the high prevalence of hepatitis B infection.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp
#What Are the Key Projections for the CAGR of the Chronic Hepatitis B Market From 2025 to 2034?
The increase in the market size of chronic hepatitis B has been constant over the past few years. It is estimated to expand from $3.77 billion in 2024 to $3.94 billion in 2025, with a compound annual growth rate (CAGR) of 4.5%. Factors contributing to this growth during the historic period include advancements in antiviral treatments, heightened efforts from government bodies and NGOs, betterment in diagnostic methods, an escalation in HIV cases, and enhanced awareness.
The market for chronic hepatitis B is projected to experience consistent growth in the forthcoming years. The market is expected to expand to $4.65 billion by 2029, with an estimated CAGR of 4.2%. The growth anticipated throughout the forecast period can be linked to factors such as growth in emerging markets, increased government policies and funding, advancements in diagnostics and screening, hike in healthcare spending, rising strategic collaborations and partnerships, an aging population growth, and increased campaigns to raise public awareness. Key trends expected during the forecast period include a shift towards curative treatments, emerging market expansions, improved diagnostics and screening, strategic partnerships and collaborations, as well as an emphasis on patient-centric care.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112
What Are the Key Market Innovations in theChronic Hepatitis B Market Over the Coming Years?
Leading corporations in the chronic hepatitis B market are concentrating on innovations like novel antiviral therapies. These cutting-edge treatments are developed to target viral infections, particularly those that exhibit resistance, by preventing replication and incorporating advanced delivery methods. In particular is bepirovirsen for chronic hepatitis B which is undergoing several clinical tests for safety and efficacy. Take for example, GSK plc – a multinational pharmaceutical and biotechnology enterprise based in the UK, with expertise in the discovery, creation, production and marketing of a diverse array of healthcare items. In February 2024, they obtained the Fast Track designation from the U.S. Food and Drug Administration (FDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Bepirovirsen is created to target and breakdown the hepatitis B virus (HBV) RNA, possibly enabling the immune system to regain authority over the infection. Efficacy has been demonstrated in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it proved efficient in minimizing hepatitis B surface antigen (HBsAg) levels and maintaining prolonged viral suppression.
Who Are the Top Companies Driving Innovation and Growth in theChronic Hepatitis B Market?
Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Which Key Market Segments Comprise the Chronic Hepatitis B Market and Drive Its Revenue Growth?
The chronic hepatitis B market covered in this report is segmented –
1) By Drug Class: Antivirals, Immune Modulators
2) By Gender: Male, Female
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp
Which Regions Are Emerging as Leaders in the Chronic Hepatitis B Market?
North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2025, By The Business Research Company:
Chronic Pain Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report
Chronic Kidney Disease Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report
Chronic Disease Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
